Assignee
UNIV WUERZBURG J MAXIMILIANS
DE·37 granted patents·63 pending applications·24 citations·filing 2007–2025
Top patents by PatentIndex Score
100 records- 0188US11760795B2Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancerUNIV WUERZBURG J MAXIMILIANS·Filed 2020·Granted Sep 19, 2023·2 cites·32 claims
- 0288US11634482B2Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancerUNIV WUERZBURG J MAXIMILIANS·Filed 2020·Granted Apr 25, 2023·2 cites·15 claims
- 0387US11262360B2GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockersUNIV WUERZBURG J MAXIMILIANS·Filed 2016·Granted Mar 1, 2022·4 cites·10 claims
- 0487US10604565B2Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancerUNIV WUERZBURG J MAXIMILIANS·Filed 2018·Granted Mar 31, 2020·6 cites·18 claims
- 0587US2024189339A1MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic PurposesUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 0683US11464856B2Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockersUNIV WUERZBURG J MAXIMILIANS·Filed 2016·Granted Oct 11, 2022·3 cites·18 claims
- 0783US2026008841A1Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancerUNIV WUERZBURG J MAXIMILIANS·Filed 2025·Application pending·0 cites
- 0882US2023382987A1Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and usesthereof for treating cancer cachexia and cancerUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 0981US2023028937A1MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic PurposesUNIV WUERZBURG J MAXIMILIANS·Filed 2022·Application pending·0 cites
- 1080US11149073B2ROR1-specific chimeric antigen receptors (CAR) with humanized targeting domainsUNIV WUERZBURG J MAXIMILIANS·Filed 2018·Granted Oct 19, 2021·3 cites·14 claims
- 1180US2024239882A1Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)UNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 1277US2023408521A1Gdf-15 as a diagnostic marker for melanomaUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 1375US11427644B2Dual antigen-induced bipartite functional complementationUNIV WUERZBURG J MAXIMILIANS·Filed 2019·Granted Aug 30, 2022·2 cites·16 claims
- 1475US11377463B2Class of sucrose esters and a method for their preparationUNIV WUERZBURG J MAXIMILIANS·Filed 2018·Granted Jul 5, 2022·2 cites·7 claims
- 1572US12473354B2GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockersUNIV WUERZBURG J MAXIMILIANS·Filed 2022·Granted Nov 18, 2025·0 cites·11 claims
- 1672US2021113603A1MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic PurposesUNIV WUERZBURG J MAXIMILIANS·Filed 2020·Application pending·0 cites
- 1771US2023416338A1Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulationUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 1870US2023277591A1Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemiaUNIV WUERZBURG J MAXIMILIANS·Filed 2022·Application pending·0 cites
- 1969US2020069720A1MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic PurposesUNIV WUERZBURG J MAXIMILIANS·Filed 2019·Application pending·0 cites
- 2069US2023310432A1Control and modulation of the function of gene-modified chimeric antigen receptor t cells with dasatinib and other tyrosine kinase inhibitorsUNIV WUERZBURG J MAXIMILIANS·Filed 2022·Application pending·0 cites
- 2168US10434117B2MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposesUNIV WUERZBURG J MAXIMILIANS·Filed 2018·Granted Oct 8, 2019·0 cites·10 claims
- 2268US2023093412A1Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockersUNIV WUERZBURG J MAXIMILIANS·Filed 2022·Application pending·0 cites
- 2367US11999764B2Class of sucrose esters and a method for their preparationUNIV WUERZBURG J MAXIMILIANS·Filed 2022·Granted Jun 4, 2024·0 cites·2 claims
- 2467US2025361284A1Transposase fusion proteins for use in cell and gene therapyUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 2566US2025115655A1Pharmaceuticals and devices for the covalent immobilization to the extracellular matrix by transglutaminaseUNIV WUERZBURG J MAXIMILIANS·Filed 2024·Application pending·0 cites
- 2665US10028974B2MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposesUNIV WUERZBURG J MAXIMILIANS·Filed 2017·Granted Jul 24, 2018·0 cites·11 claims
- 2765US2020386758A1Gdf-15 as a diagnostic marker for melanomaUNIV WUERZBURG J MAXIMILIANS·Filed 2020·Application pending·0 cites
- 2865US2025205323A1Mhc ib-mediated islet-antigen-specific immunosuppression as a novel treatment for type 1 diabetesUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 2964US2022340681A1Dual antigen-induced bipartite functional complementationUNIV WUERZBURG J MAXIMILIANS·Filed 2022·Application pending·0 cites
- 3063US2025222083A1Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody diseaseUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 3163US2025205322A1Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmoUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 3263US2025205321A1Mhc ib-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's diseaseUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 3362US2025064762A1A substituted aromatic dicarbonic acid amide as an inhibitor of the ferroptosis suppressor protein-1 (fsp1)UNIV WUERZBURG J MAXIMILIANS·Filed 2022·Application pending·0 cites
- 3461US2025228947A1Metal-organic frameworks as solid self-microemulsifying drug delivery systemsUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 3561US2024132818A1Device for fabricating a perfusable three-dimensional tissue constructUNIV WUERZBURG J MAXIMILIANS·Filed 2022·Application pending·0 cites
- 3660US2021169880A1Control and modulation of the function of gene-modified chimeric antigen receptor t cells with dasatinib and other tyrosine kinase inhibitorsUNIV WUERZBURG J MAXIMILIANS·Filed 2018·Application pending·0 cites
- 3760US2025295693A1Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)UNIV WUERZBURG J MAXIMILIANS·Filed 2022·Application pending·0 cites
- 3858US2020206266A1Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemiaUNIV WUERZBURG J MAXIMILIANS·Filed 2018·Application pending·0 cites
- 3957US12139579B2Gel-forming block copolymersUNIV WUERZBURG J MAXIMILIANS·Filed 2020·Granted Nov 12, 2024·0 cites·18 claims
- 4057US2019153157A1Thermogelling supramolecular sponge as self-healing and biocompatible hydrogelUNIV WUERZBURG J MAXIMILIANS·Filed 2019·Application pending·0 cites
- 4157US2022064258A1Ror1-specific chimeric antigen receptors (car) with humanized targeting domainsUNIV WUERZBURG J MAXIMILIANS·Filed 2021·Application pending·0 cites
- 4257US2019004047A1Gdf-15 as a diagnostic marker for melanomaUNIV WUERZBURG J MAXIMILIANS·Filed 2016·Application pending·0 cites
- 4356US2023303975A1Modified lymphocytesUNIV WUERZBURG J MAXIMILIANS·Filed 2021·Application pending·0 cites
- 4456US2025277046A1Antibody-based soluble and membrane-bound tweak mimicking agonists with fcyr-independent activityUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 4556US2026092124A1Anti-cd40 antibody constructs with high intrinsic agonismUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 4655US2023242641A1Slamf7 carsUNIV WUERZBURG J MAXIMILIANS·Filed 2021·Application pending·0 cites
- 4755US2023287129A1Siglec-6-binding polypeptidesUNIV WUERZBURG J MAXIMILIANS·Filed 2021·Application pending·0 cites
- 4855US2025304958A1Method and molecules for reducing axonal tau protein accumulation through blocking of hnrnp r-mediated mapt mrna transport for treatment of alzheimer's diseaseUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 4955US2026001937A1Novel recombinant fibrinogen variants for fibrin sealants for surgical wound careUNIV WUERZBURG J MAXIMILIANS·Filed 2023·Application pending·0 cites
- 5055US2022047697A1Salmonella vaccine for the treatment of coronavirusUNIV WUERZBURG J MAXIMILIANS·Filed 2021·Application pending·0 cites
Showing the top 50 of 100 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when UNIV WUERZBURG J MAXIMILIANS files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →